Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 4/20 | 1.00 |
| ▸ | CD40LG | P29965 | 4/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.57 |
| ▸ | PLAU | P00749 | 7/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549077 | 0.88 | CD40 (0.78) | CD40CD40LGPTPN1PLAUHTT | |
| SCHEMBL22531352 | 0.88 | CD40 (0.78) | CD40CD40LGPTPN1PLAUHTT | |
| SCHEMBL19020634 | 0.87 | CD40 (0.77) | CD40CD40LGPTPN1MEN1KMT2A | |
| SCHEMBL20590980 | 0.83 | CD40 (1.00) | CD40CD40LGNPC1RAB9AATM | |
| SCHEMBL19020654 | 0.82 | CD40 (0.69) | CD40CD40LGNPC1RAB9AMEN1 | |
| SCHEMBL22545501 | 0.79 | CD40 (0.65) | CD40CD40LGPTPN1PLAUHTT | |
| SCHEMBL19021224 | 0.78 | CD40 (0.92) | CD40CD40LGNPC1RAB9AMEN1 | |
| SCHEMBL24516452 | 0.77 | CD40 (0.62) | CD40CD40LGPTPN1PLAUHTT | |
| SCHEMBL6242038 | 0.77 | CD40 (0.61) | CD40CD40LGNPC1RAB9AMEN1 | |
| SCHEMBL19020655 | 0.77 | CD40 (0.87) | CD40CD40LGNPC1RAB9AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250277048-A1 | THE USE OF CD40 INHIBITORS FOR INHIBITING AN IMMUNE RESPONSE AND ENABLING IMMUNOGEN ADMINISTRATION AND RE-ADMINISTRATION | REGENERON PHARMACEUTICALS, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| US-20250276092-A1 | METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE | REGENERON PHARMA (US) | 2025-09-04 | — | — | US | disclosed |
| EP-3389781-B1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | UNIV MIAMI (US) | 2021-08-11 | — | — | EP | disclosed |
| US-10562848-B2 | Inhibitors of TNF superfamily costimulatory interactions and methods for uses of the same | UNIVERSITY OF MIAMI (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017106436-A1 | INHIBITORS OF TNF SUPERFAMILY COSTIMULATORY INTERACTIONS AND METHODS FOR USES OF THE SAME | UNIVERSITY OF MIAMI (US) | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562848-B2 | Inhibitors of TNF superfamily costimulatory interactions and methods for uses of the same | CD40, TNFRSF9, TNFRSF1A | CD40 1/4885CD40LG 7/4885PTPN1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.